Düsseldorf / Neuss - The (KVNO) and the AOK Rheinland / Hamburg have concluded an agreement that is intended to promote quality-oriented and guideline-compliant long-term treatment of patients with schizophrenia. The new care concept combines long-term drug treatment with scientifically recognized accompanying therapies. The aim is to reduce the relapse rate, improve adherence to therapy, avoid stressful hospital admissions and noticeably improve the patient's quality of life. "The promotion of continuous therapy over several years can reduce the risk of disease recurrence by up to two thirds," explains Cornelia Prüfer-Storcks, board member of. North Rhine-Westphalia AOK insured persons with schizophrenia can now enroll in the program.